Latest long-term debt for XENE: $5.1M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), XENE shows a long-term debt of $5.1M. That compares with $7.3M in the prior-year period — down 30.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, XENE's long-term debt is now $5.1M (was $7.3M) — a 30.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Xenon Pharmaceuticals is outperforming or lagging.
Tracking XENE's long-term debt over time shows whether Xenon Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $5.1M That compares with $7.3M in the prior-year period — down 30.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Xenon Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $5.1M) with ownership activity and broader fundamentals.
Xenon Pharmaceuticals's long-term debt is $5.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.